Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Status:
Recruiting
Trial end date:
2025-07-25
Target enrollment:
Participant gender:
Summary
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body
(pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of
i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia
rheumatica (PMR).